Abstract：Objective To analyze the clinical data of children with invasive pneumococcal disease (IPD) or noninvasive pneumococcal disease (NIPD), and to provide a reference for clinical diagnosis and treatment. Methods A retrospective analysis was performed on the medical data and the drug susceptibility test results of isolated strains of 518 children who were hospitalized due to Streptococcus pneumoniae (SP) infection from January 2013 to December 2017. According to the location of the isolated strains, the children were divided into an IPD group with 35 children and an NIPD group with 483 children. Results The children with IPD had a median age of 2.2 years, and the children aged ≤5 years accounted for 80.0%. For the children with IPD, the main type of infection was meningitis which was observed in 19 children (54.3%), and the most common underlying disease was hematological malignancy in 8 children (22.9%); 14 children (40.0%) were admitted to the pediatric intensive care unit (PICU), 18 children (51.4%) experienced complications, and 8 children (22.9%) died. For the children with NIPD, the median age was 1.2 years; the main type of infection was pneumonia in 429 children (88.8%), and the most common underlying disease was congenital heart disease in 60 children (12.4%); 60 children (12.4%) were admitted to the PICU, 102 children (21.1%) experienced complications, and 11 children (2.3%) died. The IPD group had significantly higher incidence rate of complications, PICU admission rate, and mortality rate than the NIPD group (P < 0.01). The invasive SP strains had a significantly lower susceptibility rate to penicillin than noninvasive SP strains (68.6% vs 94.2%, P < 0.01). Conclusions SP infection is common in children under 5 years of age, and the children with underlying diseases including hematological malignancy are at high risk for IPD. Although the complication rate, PICU admission rate, and mortality rate of NIPD children are lower than those of IPD children, they still cannot be ignored. Penicillin may be used as an empirical treatment for children with NIPD, but not for those with IPD.
GUO Ying,QIAO Li-Na. Clinical features and antibiotic sensitivity of invasive pneumococcal disease versus noninvasive pneumococcal disease in children[J]. CJCP, 2021, 23(5): 466-470.
Fitzgerald D, Waterer GW. Invasive pneumococcal and meningococcal disease[J]. Infect Dis Clin North Am, 2019, 33(4):1125-1141.
[2]
Backhaus E, Berg S, Andersson R, et al. Epidemiology of invasive pneumococcal infections:manifestations, incidence and case fatality rate correlated to age, gender and risk factors[J]. BMC Infect Dis, 2016, 16:367.
[3]
Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries[J]. Vaccine, 1999, 17(7-8):646-652.
Clinical and Laboratory Standards Institute. M100 performance standards for antimicrobial susceptibility testing:28th edition[EB/OL]. (2018-01-24)[2020-11-20].
[10]
Centers for Disease Control and Prevention (CDC). Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015[J]. MMWR Morb Mortal Wkly Rep, 2006, 55(18):511-515.
[11]
Kaplan SL, Barson WJ, Lin PL, et al. Invasive pneumococcal disease in children's hospitals:2014-2017[J]. Pediatrics, 2019, 144(3):e20190567.
[12]
Butters C, Phuong LK, Cole T, et al. Prevalence of immunodeficiency in children with invasive pneumococcal disease in the pneumococcal vaccine era:a systematic review[J]. JAMA Pediatr, 2019, 173(11):1084-1094.
[13]
Haddad MB, Porucznik CA, Joyce KE, et al. Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996-2002[J]. Ann Epidemiol, 2008, 18(2):139-146.
[14]
Hjuler T, Wohlfahrt J, Staum Kaltoft M, et al. Risks of invasive pneumococcal disease in children with underlying chronic diseases[J]. Pediatrics, 2008, 122(1):e26-e32.
Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries:an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study[J]. Antimicrob Agents Chemother, 2012, 56(3):1418-1426.
Wang CY, Chen YH, Fang C, et al. Antibiotic resistance profiles and multidrug resistance patterns of Streptococcus pneumoniae in pediatrics:a multicenter retrospective study in mainland China[J]. Medicine (Baltimore), 2019, 98(24):e15942.
[20]
Jorgensen JH, McElmeel ML, Fulcher LC, et al. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in Streptococcus pneumoniae[J]. J Clin Microbiol, 2011, 49(9):3332-3333.
[21]
Levy C, Varon E, Béchet S, et al. Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children[J]. Clin Infect Dis, 2016, 62(1):131-132.
[22]
Liao WH, Lin SH, Lai CC, et al. Impact of pneumococcal vaccines on invasive pneumococcal disease in Taiwan[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(4):489-492.
